Alergozan film-coated tablets 5 mg No. 10

Allergosan ® tablets are prescribed to adults and children over 12 years of age to relieve symptoms associated with:

Composition

The active substance is desloratadine (one tablet contains 5 mg of desloratadine).

Excipients: microcrystalline cellulose, calcium hydrogen phosphate dihydrate, corn starch, hypromellose, talc, sodium stearyl fumarate, colloidal anhydrous silicon dioxide; film coating: Opadry II 33G 205 005 blue (hypromellose, lactose monohydrate, titanium dioxide (E 171), macrogol 3350, triacetin, indigo carmine aluminum lake (E 132), quinoline yellow aluminum lake (E 104)).

Contraindication

Hypersensitivity to the active substance or to any of the excipients of the drug or to loratadine.

Method of application

Administer orally, regardless of meals.

Adults and children over 12 years of age: one tablet once a day is recommended, regardless of meals, to eliminate symptoms associated with allergic rhinitis (including intermittent and persistent allergic rhinitis) and urticaria.

Therapy of intermittent allergic rhinitis (presence of symptoms less than 4 days per week or less than 4 weeks) should be carried out taking into account the anamnesis: stop after the symptoms disappear and resume after their reappearance.

With persistent allergic rhinitis (presence of symptoms for more than 4 days a week or more than 4 weeks), treatment must be continued throughout the entire period of contact with the allergen.

Application features

Pregnant women

Desloratadine has not been shown to be teratogenic in animal studies. The safety of the drug during pregnancy has not been established, therefore the use of desloratadine during this period is not recommended.

Desloratadine passes into breast milk, so its use in breastfeeding women is not recommended.

Children

There are limited clinical trial data on the efficacy of desloratadine in adolescents aged 12 to 17 years.

There are no established data on the efficacy and safety of desloratadine in children under 12 years of age.

Drivers

In clinical trials evaluating the ability to drive, no impairment was observed in patients taking desloratadine. However, patients should be informed that very rarely some people experience drowsiness, which may affect their ability to drive or operate machinery.

Overdose

In case of overdose, adverse reactions are similar to those observed in therapeutic doses, but the manifestations may be stronger.

Symptoms: In clinical studies in which desloratadine was administered at doses up to 45 mg (9 times the recommended dose), no clinically significant adverse reactions were observed.

Treatment. In case of overdose, standard measures should be taken to remove unabsorbed active substance. Symptomatic and supportive treatment is recommended. Desloratadine is not removed by hemodialysis; its removal by peritoneal dialysis has not been established.

Side effects

The most frequently reported adverse reactions compared to placebo were fatigue (1.2%), dry mouth (0.8%), and headache (0.6%).

Storage conditions

Store at a temperature not exceeding 25 °C, out of the reach of children.

Shelf life - 2 years.